Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    5

Stocks News & Analysis

stocks

What next for Tesla as 2024 deliveries disappoint?

Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks

Best and worst performing ASX sectors of 2024

Exploring the ASX sectors that moved the market this year.
stocks

2 ASX companies with the traits of a long-term winner

Two companies that show promising signs of handsomely rewarding shareholders.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,511.9046.900.55%
CAC 407,393.7613.020.18%
DAX 4020,024.66115.520.58%
Dow JONES (US)42,392.27151.95-0.36%
FTSE 1008,260.0987.071.07%
HKSE19,704.1680.840.41%
NASDAQ19,280.7930.00-0.16%
Nikkei 22539,894.54386.62-0.96%
NZX 50 Index13,067.8342.91-0.33%
S&P 5005,868.5513.08-0.22%
S&P/ASX 2008,250.5049.300.60%
SSE Composite Index3,211.4351.13-1.57%

Market Movers